Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis

Journal of Crohn's and Colitis

Volumn 3, Issue 4, 2009, Pages 271-276

  Barreiro de Acosta, Manuel ^a   Lorenzo, Aurelio ^a   Mera, Jose ^a   Dominguez Muñoz, J Enrique ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Infliximab; Maintenance treatment; Mucosal healing; Steroid dependent; Ulcerative colitis

Indexed keywords

INFLIXIMAB; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLONOSCOPY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INTESTINE MUCOSA; MALE; PRIORITY JOURNAL; REMISSION; ULCER HEALING; ULCERATIVE COLITIS;

EID: 70350622433     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.06.003     Document Type: Article

References (37)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
2. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2 (1955) 1041-1048
3. Stange E.F., Travis S.P., Vermeire S., Reinisch W., et al. European evidence based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. European Crohn's and Colitis Organisation (ECCO). J Crohns Colitis 2 1 (2008) 1-21
4. Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
5. Langholz E., Munkholm P., Davidsen M., and Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107 (1994) 3-11
6. Bianchi Porro G., Cassinotti A., Ferrara E., Maconi G., and Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 26 (2007) 779-794
7. Lennard-jones J.E., Misiewick J.J., Connell A.M., Baron J.H., and Jones F.A. Prednisone as mainteinance treatment for ulcerative colitis in remission. Lancet 1 (1965) 188-189
8. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
9. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., and Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55 (2006) 47-53
10. Dubinsky M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2 (2004) 731-743
11. Sands B.E. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?. Gut 55 (2006) 437-441
12. Rutgeerts P., Vermeire S., and Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 56 (2007) 453-455
13. Sands B.E., Tremaine W.J., Sandborn W.J., Rutgeerts P.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7 (2001) 83-88
14. Probert C.S., Hearing S.D., Schreiber S., Kühbacher T., et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52 (2003) 998-1002
15. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
16. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol, Suppl 170 (1989) 2-6
17. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A (2005) 5-36
18. Stange E.F., Travis S.P., Vermeire S., and Beglinger C. (European Crohn's and Colitis Organisation). European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 55 Supplement 1 (2006) i1-i15
19. Sutherland L.R., Martin F., Greer S., Robinson M., et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92 (1987) 1894-1898
20. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., and Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56 (2007) 1226-1231
21. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
22. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
23. Järnerot G., Hertervig E., Friis-Liby I., Blomquist L., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
24. Kohn A., Daperno M., Armuzzi A., Cappello M., et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 26 (2007) 747-756
25. Lees C.W., Heys D., Ho G.T., Noble C.L., et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 26 (2007) 411-419
26. Jakobovits S.L., Jewell D.P., and Travis S.P. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 25 (2007) 1055-1060
27. Willert R.P., and Lawrance I.C. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 14 (2008) 2544-2549
28. Gisbert J.P., González-Lama Y., and Maté J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 25 (2007) 19-37
29. Armuzzi A., De Pascalis B., Lupascu A., Fedeli P., et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 8 (2004) 231-233
30. Gavalas E., Kountouras J., Stergiopoulos C., Zavos C., et al. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology. 54 (2007) 1074-1079
31. Beattie R.M., Nicholls S.W., Domizio P., Williams C.B., and Walker-Smith J.A. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 22 (1996) 373-379
32. D'Ovidio V., Aratari A., Viscido A., Marcheggiano A., et al. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis. Dig Liver Dis 38 (2006) 389-394
33. Emmrich J., Petermann S., Nowak D., Beutner I., et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis-results of a randomized pilot trial. Dig Dis Sci 52 (2007) 2044-2053
34. Ricart E., García-Bosch O., Ordás I., and Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 14 (2008) 5523-5527
35. Ferrante M., Vermeire S., Katsanos K.H., Noman M., et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 13 (2007) 123-128
36. Vermeire S., Louis E., Carbonez A., Van Assche G., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 97 (2002) 2357-2363
37. Parsi M.A., Achkar J.P., Richardson S., Katz J., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 (2002) 707-713